Serum metabolomics dataset from paper titled "Relapsing remitting and secondary progressive multiple sclerosis are characterised by distinct metabolomic and transcriptomic signatures that could aid patient management strategies"

Description

Peripheral blood was collected from patients with relapsing-remitting MS (RRMS, n=52) and secondary progressive MS (SPMS, n=29), diagnosed according to the revised McDonald criteria (Polman et al., 2011). Patients with RRMS were disease modifying treatment naive. As controls peripheral blood from healthy donors (HCs, n=80) and patients with neuromyelitis optica (disease controls - DCs, n=30, an autoantibody-mediated disease that shares some symptoms and may be misdiagnosed as MS) was also collected. Ethical approvals for this work were obtained from the University College London Hospitals National Health Service Trust research ethics committee (Reference numbers 18/SC/0323 – RELOAD-MS study; 15-LO-2065, 16/YH/0306, and 15/SW/0109- ABIRISK study) and the Medical Ethics Committee of the General University Hospital in Prague (125/12 and Evropský grant 1.LF UK-CAGEKID). All participants provided informed written consent in accordance with the Declaration of Helsinki. Measures of 250 serum biomarkers were acquired with a well-established nuclear magnetic resonance (NMR)-spectroscopy platform (Nightingale Health). These included both absolute concentrations, percentages, and ratios of lipoprotein composition. Serum lipids measured included apolipoproteins (Apo) and (very) low density ((V)LDL), intermediate density (IDL) and high density (HDL) lipoprotein particles of different sizes ranging from chylomicrons and extremely large (XXL), very large (XL), large (L), medium (M), small (S), and very small (XS). Contact authors for basic demographic information on participants.

Institutions

Categories

Funding

Licence